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Abstract
Background One-lung ventilation (OLV) procedures are essential for most thoracic surgeries, and the most common method 
is intubation with a conventional double-lumen tube (cDLT) and bronchoscopy to verify correct tube placement.
Objective The objective of this study was to conduct a cost-effectiveness analysis comparing the VivaSight double-lumen 
tube (DL) and a cDLT for OLV procedures.
Methods A cost-effectiveness analysis was conducted from a healthcare sector perspective in Denmark using a decision 
analytic model to assess the potential effects and costs of using VivaSight-DL as an alternative to a cDLT with a reusable 
bronchoscope. Costs were determined using a micro-costing approach. The effectiveness measure was the number of times 
that fiberoptic confirmation of the tube placement during intubation or surgery was unnecessary and thus avoided. The 
effectiveness input was from a randomized controlled trial (n = 52). Both deterministic and probabilistic sensitivity analyses 
were conducted to assess the robustness of the results.
Results Fiberoptic confirmation of tube placement was only necessary in two (6.66%) procedures using VivaSight-DL. The 
cost of using VivaSight-DL was $US299.96 per procedure versus $US347.61 for a cDLT with a reusable bronchoscope. The 
incremental cost-effectiveness ratio was − $US51.06 per bronchoscopy avoided. The base-case analysis indicated that the 
use of VivaSight-DL was cost effective compared with the use of a cDLT with reusable bronchoscope. Sensitivity analyses 
showed that the results were robust and that VivaSight-DL was more effective and less costly.
Conclusion This study suggests that VivaSight-DL is associated with cost savings and reductions in bronchoscope use to 
verify correct tube placement. The conclusion is based on the results from a single institution. To clarify whether VivaSight-
DL is cost effective in larger or global clinical settings, further economic evaluations should be performed.
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 larsenbk@hotmail.com
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Key Points for Decision Makers 
Using a VivaSight double-lumen tube (VivaSight-DL) 
is cost effective compared with using a conventional 
double-lumen tube (cDLT) and reusable bronchoscopes.
The use of a bronchoscope to verify correct tube 
placement can be significantly reduced with the use of 
VivaSight-DL.
VivaSight-DL is easy to place and is associated with 
significantly less repositioning both during intubation 
and during the procedure.
1 Introduction
One-lung ventilation (OLV) is an essential technique for 
most classic thoracic surgeries and refers to the mechani-
cal separation of the lungs, whereby one lung is venti-
lated and the other is deflated [1–4]. The most common 
OLV method is intubation with a double-lumen tube 
(DLT) [1–3, 5]. Indications for OLV procedures are often 
lobectomies, biopsies for suspicion of cancer, and lung 
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resections. In Denmark, approximately 2100 OLV pro-
cedures are conducted annually [6]. OLV procedures are 
common in clinical settings and are generally considered 
safe, with only minor complications such as sore throat, 
fever, and hoarseness [3, 7, 8]. However, the reusable 
bronchoscopes used in various thoracic surgeries to check 
for and ensure correct placement of the DLT carry a risk 
of cross-contamination between patients and subsequent 
infection [8–11].
DLTs can be difficult to insert and are likely to move 
during changes in patient position and surgery, which may 
compromise patient safety and prolong surgery time [5, 12, 
13]. Furthermore, the gold standard practice is to check for 
correct tube placement using a fiberoptic or video-enabled 
bronchoscope both after tube insertion and after chang-
ing the patient’s position to the final lateral surgical posi-
tion, which further increases the risk of tube displacement 
[7, 14]. Therefore, continuous visualization of the tube’s 
position in the main bronchus is thought to ensure more 
accurate and safer tube placement, significantly reducing 
the number of failed intubations, and the time spent veri-
fying placement [5, 12, 13]. The VivaSight-DL (ETView 
Medical Ltd./Ambu A/S, Ballerup, Denmark) is the only 
fully single-use DLT with an integrated camera, which 
allows for more accurate tube placement using continuous 
real-time visualization and airway control during the entire 
surgical procedure [1, 7, 15].
Reusable bronchoscopes are thought to be associated 
with high repair costs, reprocessing costs, and possible 
transmission of infectious agents via cross-contamina-
tion, which further increases the economic burden [3, 7, 
8, 16–18]. Furthermore, using bronchoscopy to ensure 
correct tube placement may prolong the intubation proce-
dure time compared with VivaSight-DL, which allows for 
immediate confirmation of tube placement with continu-
ous visualization [12, 19]. Incorrect placement of the DLT 
can lead to problems with deflating the lung or with venti-
lating the non-operative lung sufficiently. Therefore, visual 
confirmation of correct tube placement after intubation 
and after placing the patient in the lateral surgical position 
has become mandatory [5, 15]. Since its introduction in 
1982, fiberoptic bronchoscopy has been used to confirm 
and maintain proper placement of the tube during OLV. 
However, studies have shown that fiberoptic bronchos-
copy is associated with a high incidence of malposition 
(35–48%), leading to additional time spent on subsequent 
repositioning [15, 20, 21].
In addition, reusable bronchoscopes incur costs related 
to purchasing, reprocessing (involving high-level disinfec-
tion), and general maintenance and repair, which are all 
expected to increase in the future given the expected larger 
disease burden and more hospitals conducting more proce-
dures annually [15, 22, 23]. The objective of this study was 
to investigate the cost effectiveness of using VivaSight-DL 
instead of cDLTs.
2  Methods
2.1  Study Design
A decision analytic model was constructed to assess the 
potential costs and effects associated with VivaSight-DL 
compared with a cDLT in a cost-effectiveness analysis 
(Fig. 1). Costs of reusable bronchoscopes, including capi-
tal costs and costs associated with reprocessing, personnel, 
maintenance, and repair, were obtained using a 10-year time 
horizon. Costs related to VivaSight-DL were obtained using 
a 24-h time horizon. All costs are presented in $US, and 
adjusted to year 2018 values, with a discount rate of 3.5% 
regarding capital expenditures. The effectiveness measure 
for the cost-effectiveness analysis (CEA) was the number of 
times that fiberoptic confirmation of the tube placement dur-
ing intubation or surgery was unnecessary and thus avoided. 
Effect data were obtained from a randomized controlled trial 
(RCT) and used to inform the decision model. The analy-
sis was conducted from a healthcare sector perspective in 
Denmark, and the decision analytic model was constructed 
using the software TeeAgePro 2018 (TreeAge Software, Inc, 
Massachusetts, USA) (Fig. 1).
2.2  Trial Design
In the RCT, 50 patients were randomly assigned to two 
groups using a computer-generated random number list 
(http://www.rando mizer .org). The intervention group was 
assigned to undergo intubation using VivaSight-DL, and 
the control group was assigned to undergo intubation using 
a cDLT (Shiley™ Medtronic, Minnesota, USA). Dropouts 
in both groups meant it was necessary to randomly assign 
Fig. 1  Decision analytic model for cost effectiveness of VivaSight-
double-lumen (DL) tube vs. conventional double-lumen tube (cDLT)
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20 additional subjects to reach a total minimum number of 
50 fully evaluable patients.
2.2.1  Study Population
Patients were eligible for inclusion if they were admitted 
to Unit BTY, Department V, Odense University Hospital 
(OUH), Denmark, and if they were evaluated as being eli-
gible for an OLV with the use of a left-sided DLT. Patients 
were excluded if they had known tracheobronchial ana-
tomic anomalies or tracheal pathology, had anticipated dif-
ficult airways, were aged < 18 years, were undergoing an 
emergency procedure, required rapid sequence induction or 
right-sided DLT, had a prior systematic infection or sus-
pected tuberculosis, or were unsuited for intubation with a 
DLT (VivaSight-DL or cDLT). Lastly, patients who needed 
surgeries in which the use of other lung isolation devices or 
techniques was likely to be warranted (tracheostomy, nasal 
intubation, etc.) were excluded. Physicians were eligible for 
participation if they had experience with DLT-associated 
intubations involving fewer than 50 patients, had completed 
the simulation training course, and had experience with at 
least ten cDLT placements and three VivaSight-DL place-
ments involving a training manikin. Novice physicians were 
included to reflect real-world clinical settings, as the RCT 
was conducted at a university hospital.
2.3  Resource Use and Costs
Data on the utilization of resources and unit costs related 
to the cDLT and reusable bronchoscopes were obtained 
from OUH. All costs occurring before 2018 were adjusted 
using the average consumer price index for the year the 
cost occurred [24]. Finally, all costs were converted to $US 
(exchange rate $US1 = DKK6.55; 7 February 2019).
2.3.1  Micro‑Costing Analysis
A micro-costing analysis was carried out to obtain cost 
inputs for the CEA. The micro-costing approach was cho-
sen because it allows for precise assessment of economic 
costs [25]. The purpose of the analysis was to determine 
the cost per use of a cDLT with a reusable bronchoscope 
compared with the cost per use of VivaSight-DL. Regarding 
the VivaSight-DL group, in cases in which bronchoscopy 
was required, both a single-use bronchoscope (aScope™ 
4 Broncho, Ambu A/S) and reusable bronchoscopes were 
considered in the analysis.
Therefore, several procedures involving bronchoscopy 
and the reprocessing procedure were observed in detail. All 
capital costs related to the cleaning equipment, including 
the automated endoscope reprocessor (AER) and the dry-
ing cabinets, were amortized over an 8-year period. The 
8-year amortization period was based on the average age 
of the drying cabinets and AER. A discount rate of 3.5% 
was used to calculate the present value of capital expendi-
tures. Reusable bronchoscopes were amortized over a 6-year 
period, which was selected based on the average age of the 
six bronchoscopes currently available at OUH [26, 27]. The 
micro-costing analysis was carried out in regards to capital 
costs, reprocessing costs, and repair and maintenance costs.
Additionally, the total intubation time, number of intuba-
tion attempts, number of times the tube needed to be reposi-
tioned during surgery, and time spent by the backup anesthesi-
ologist assisting the novice physician were accurately assessed 
during the RCT. The intubation time was defined as the time 
from introduction of the laryngoscope blade into the patient’s 
mouth until correct tracheal cuff placement confirmed by cap-
nography. All clinical data were measured and obtained by the 
physicians and other personnel themselves. Lastly, a total of 
ten bronchoscopy procedures were monitored by the inves-
tigator to estimate the average time spent on bronchoscopy 
involving a fiberoptic or video-enabled bronchoscope.
2.3.2  Reprocessing and Repair Costs
Cost estimates related to reprocessing and repair of the reus-
able bronchoscopes were based on the six bronchoscopes 
available at Unit BTY, Department V, OUH. This analysis 
involved the mean annual number of bronchoscopy proce-
dures (n = 600), mean reprocessing time, and mean annual 
cost of repairs. Maintenance of the reprocessing equipment 
was managed by medical engineers at OUH, and no records 
were kept of previous repairs or services, so these costs were 
based on the literature adjusted by − 20% to avoid overestima-
tion [28]. Materials related to reprocessing such as consuma-
bles were accounted for. Reprocessing costs were divided 
into costs for reprocessing equipment, manual precleaning, 
drying, and AER running costs. A detailed description of the 
reprocessing materials and costs is provided in Table 1. The 
hourly wage of cleaning personnel was calculated based on 
2018 wages and an estimate of 1500 productive working hours 
annually. Costs related to the training and education of clean-
ing personnel were not included, as these data were not avail-
able at OUH. Purification of the water used by the AER was 
centralized in the basement of the hospital and thus a water 
disinfector was not required. Therefore, it was not possible to 
calculate the costs of purifying the water.
2.4  Effectiveness Measure
The number of times that fiberoptic confirmation of the tube 
placement during intubation or surgery was unnecessary and 
thus avoided was chosen as the effectiveness measure. The 
effectiveness measure was chosen due to the assumption that 
fiberoptic confirmation using a bronchoscope is both time 
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consuming and costly. Although intubation time is an indi-
cator of the relative ease of correct tube placement, it is not 
a sufficient effectiveness measure, as it reflects physician 
competences and varies greatly between patients because of 
differences in airway anatomy and health status.
2.5  Sensitivity Analyses
A number of one-way analyses were conducted to assess the 
impact on the incremental cost-effectiveness ratio (ICER) 
of varying the percentage of VivaSight-DL cases in which 
fiberoptic confirmation with a single-use bronchoscope 
(aScope™ 4 Broncho) was needed (5%, 10%, and 15%) and 
by increasing the annual number of bronchoscopy proce-
dures (800, 1000, and 1200). When increasing the annual 
number of bronchoscopy procedures, the annual repair and 
maintenance costs were proportionally increased, and the 
amount of detergent used for the AER was increased. Fur-
thermore, the maintenance cost was decreased by an addi-
tional 10%, 20%, and 30%, respectively, as the maintenance 
cost was based on the literature [28] and may be slightly 
overestimated compared with current clinical settings at 
OUH (i.e., the baseline cost was based on the literature and 
adjusted by − 20%). Lastly, the capital cost of the VivaSight-
DL device was decreased by 10%, 20%, and 30% to account 
for differences between countries.
A two-way sensitivity analysis was conducted to assess 
the impact of cost levels regarding VivaSight-DL and cDLTs 
with reusable bronchoscopes. The analysis included all costs 
directly related to the use of cDLTs with reusable broncho-
scopes. Moreover, a probabilistic sensitivity analysis (PSA) 
was conducted to simultaneously test the impact of the dif-
ferent variables and to assess the robustness of the result 
(Table 2). A second-order Monte Carlo simulation with 
10,000 simulations was used for the PSA. Gamma distribu-
tions were applied to all cost variables, as this distribution 
allows for right skewness and because the cost variables can 
only take a positive value. Beta distributions were applied 
to the probability variables, as the probabilities can only lie 
between zero and one.
2.6  Statistics
All non-cost data obtained from the RCT were stored and 
managed using Smart-Trial (http://www.smart -trial .com) 
and exported to and analyzed using Microsoft Excel 2016. 
All cost data were stored and analyzed in Excel. For both the 
intervention and control groups, means and standard devia-
tions (SDs) were determined for the baseline patient char-
acteristics, comprising age, weight, height, and body mass 
index. Two-sided Fisher’s exact tests were used to test for 
statistically significant differences between sex and number 
of patients who had a tube repositioning in the intervention 
and control groups. Furthermore, a two-sided Wilcoxon rank 
sum test was used to determine whether there was a statisti-
cally significant difference in age, height, weight, intuba-
tion attempts, intubation time, Cormack-L classification 
(classification used to describe laryngeal view during direct 
laryngoscopy [29]), use of fiberoptic bronchoscopy, preven-
tion of repositioning, repositioning time, and time spent by 
responsible anesthesiologists to assist repositioning between 
the two groups. A statistical significance level of 0.05 was 
applied.
Table 1  Reprocessing equipment. All unit costs are estimated based 
on data from Odense University Hospital. Estimated costs of mainte-
nance are based on the literature [28]
AER automated endoscope reprocessor
a BODE Chemie GmbH, Hamburg, Germany
b Getinge Sterilization AB, Getinge, Sweden
Item Cost per item/
procedure ($US)
Reprocessing equipment
 AER 21.10
 Drying cabinet 1 9.25
 Drying cabinet 2 9.25
 Drying cabinet 3 9.25
 Maintenance—drying cabinets 35.44
 Maintenance—AER 50.53
Manual precleaning
 Brushes 4.93
 Sterile water 0.12
 Ethanol 0.06
 ATP water effluent test 0.27
 Plastic packaging 0.69
 Non-sterile gloves 0.07
 Sterile wash gown 0.11
 Cover (for transport) 1.02
 Plastic cover (for transport) 0.97
 Bodedex®  fortea 4.16
 High-clean non-woven swabs 0.09
 Water 0.15
 Cleaning personnel 4.41
Drying
 Cleaning personnel 0.88
 Power 1.8
AER running costs
 DLC endoscope  detergentb 1.22
 Aperlan  Ab 3.00
 Aperlan  Bb 3.04
 Power 1.8
 Water 0.41
 Cleaning personnel (daily cleaning) 3.53
Total 167.55
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3  Results
3.1  Patient Characteristics
Of the 70 patients assessed, 18 were excluded from the 
study. All patients were admitted to Unit BTY, Department 
V, OUH for thoracic surgery from 5 November 2018 to 23 
January 2019. Of the remaining 52 eligible patients, 30 were 
allocated to the intervention group (VivaSight-DL) and 22 
to the control group (cDLT). In the intervention group, 
the mean age was 65.8 years and 13 patients (43.3%) were 
female. In the control group, the mean age was 68.5 years 
and 12 patients (54.5%) were female. While having lim-
ited statistical power, there were no significant differences 
in sex (p = 0.58), age (p = 0.44), height (p = 0.76), weight 
(p = 0.69), or Cormack-L classification (p = 0.98) between 
the intervention and control groups (p = 0.71). All baseline 
patient characteristics are shown in Table 3.
3.2  Micro‑Costing Analysis
All costs related to cDLT use, including reprocessing, 
maintenance, repair, and personnel, were calculated as 
the cost per procedure. The total cost of performing an 
intubation using a cDLT with bronchoscopy to verify the 
tube placement is $US347.61. The cost includes an addi-
tional cost of 67.88 s extra time spent on bronchoscopy, 
which amounts to an additional cost of $US39.60 using 
an estimated operating room running cost of $US35.00 
per minute [30–32]. The total cost of performing an intu-
bation using VivaSight-DL is $US299.96, including the 
cost of an  Ambu® aView™ monitor (Ambu A/S, Bal-
lerup, Denmark). The costs related to each intervention 
are specified in Table 4. Regarding the cost of each major 
activity involved in using a cDLT with bronchoscopy, the 
reprocessing cost (including the reprocessing equipment 
and personnel) was $US81.61 per procedure, the cost 
of reprocessing equipment maintenance was $US86.04, 
and the bronchoscope repair cost was $US77.13. In 
2018, the six bronchoscopes were repaired for a total of 
$US46,293.32. Capital costs, year of purchase, and repair 
cost of the bronchoscopes are provided in Table 5. 
The time spent by cleaning personnel on manually han-
dling the bronchoscopes after each procedure amounted to 
a total of 15 ± 2.76 min. A detailed description of the time 
allocation is listed in Table 6. Intubation time was meas-
ured for each procedure, and the average intubation time was 
1.66 ± 0.89 min in the intervention group and 1.43 ± 0.80 min 
Table 2  Model inputs: parameter values and their respective standard errors, distributions and source
cDLT conventional double-lumen tube, DL double-lumen tube, OUH Odense University Hospital, RCT randomized controlled trial, SE standard 
error
Parameter Base-case value (SE) Distribution Source
Effects
 cDLT and reusable colonoscope: avoided bronchoscopy 0% Beta RCT per-
formed at 
OUH (see 
Sect. 2.2)
 VivaSight-DL: avoided bronchoscopy 93.33% Beta RCT per-
formed at 
OUH (see 
Sect. 2.2)
Cost
 Cost per use of cDLT and reusable colonoscope 347.61 (16.8) Gamma OUH
 Cost per use of VivaSight-DL (incl.  Ambu® aView™) 299.96 (12) Gamma Ambu A/S
Table 3  Baseline patient characteristics of the randomized controlled 
trial
Data are presented as mean ± standard deviation or n (%)
Cormack-L-classifications: (1) full view of glottis; (2) partial view of 
glottis; (3) only view of epiglottis; (4) no view of either glottis or epi-
glottis
cDLT conventional double-lumen tube, DL double-lumen tube
VivaSight-DL (n = 30) cDLT (n = 22)
Age, years 65.8 ± 10.0 68.5 ± 7.2
Female 13 (43.3) 12 (54.5)
Male 17 (56.7) 10 (45.5)
Weight, kg 74.7 ± 19.1 76.2 ± 17.1
Height, cm 172.5 ± 9.3 172.8 ± 9.6
Body mass index, kg·cm2 24.9 ± 5.2 25.6 ± 4.4
Cormack-L classification
 I 18 (60.0) 14 (63.6)
 II 10 (33.3) 5 (22.7)
 III 1 (3.3) 1 (4.5)
 IV 1 (3.3) 2 (9.1)
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in the control group (p = 0.20). The average number of intu-
bation attempts was 1.23 ± 0.50 in the intervention group and 
1.14 ± 0.47 in the control group (p = 0.44). However, in the 
intervention group, the tube was only repositioned in three 
patients (total of four repositions, maximum two repositions 
per patient) before correct tracheal cuff placement was con-
firmed by capnography, which is significantly less than in 
the control group, in which the tube was repositioned in 11 
patients (total of 20 repositions, maximum seven repositions 
per patient) before capnography (p = 0.0034). After capnog-
raphy, the tube was repositioned in seven patients (total of ten 
repositions, maximum three repositions per patient) from the 
intervention group and in 12 patients (total of 17 repositions, 
maximum three repositions per patient) from the control 
group (p = 0.04). The average time spent on the reposition-
ing during surgery was 60.86 ± 73.09 s in the intervention 
group and 144.42 ± 152.86 s in the control group (p = 0.06). 
In total, the backup anesthesiologist assisted with reposition-
ing the tube once in the intervention group and three times 
in the control group. The backup anesthesiologist spent 18 s 
on repositioning in the intervention group and 520 s (mean 
173.33 ± 115.47) in the control group (p = 1.00). The addi-
tional cost of having the backup anesthesiologist assisting 
with repositioning was $US0.61 in the intervention group 
and $US17.64 in the control group.
3.3  Base‑Case and Sensitivity Analyses
The base-case analysis showed an average cost of a cDLT 
with a reusable bronchoscope of $US347.61, and a bron-
choscope was used to verify correct placement in all cases 
involving a cDLT. The ICER was − $US51.06 per bronchos-
copy avoided. Generally, fiberoptic confirmation is needed 
Table 4  Overall cost categories ($US per procedure) for both inter-
ventions (VivaSight-DL vs. cDLT)
cDLT conventional double-lumen tube, DL double-lumen tube
a The backup anesthesiologist spent 18 s on repositioning in the inter-
vention group
b The backup anesthesiologist spent 520 s on repositioning in the con-
trol group
Cost category VivaSight-DL cDLT
Capital costs VivaSight-DL: 299.00
Ambu® aView™: 0.94
Reusable 
bron-
cho-
scope: 
27.01
Dispos-
able 
tube: 
35.41
Repair cost None 77.13
Maintenance None 86.04
Backup anesthesiologist 0.02a 0.80b
Cleaning supplies and equip-
ment
None 72.79
Cleaning personnel None 8.82
Operating room running cost None 39.60
Total cost 299.96 347.61
Table 5  Capital and repair 
costs ($US) of reusable 
bronchoscopes in 2018
OUH Odense university hospital
a Cost per procedure was identified using the annual number of procedures performed at OUH (n = 600)
Item Capital costs Year of purchase Repair costs
Fiberoptic bronchoscope 6390.15 2016 0
Fiberoptic bronchoscope 6099.71 2016 0
Fiberoptic bronchoscope 7355.03 2009 1633.59
Video-enabled bronchoscope 24,200.26 2008 25,900.70
Video-enabled bronchoscope 23,889.46 2009 10,373.47
Video-enabled bronchoscope 18,460.41 2014 8385.58
Cost per  procedurea 27.01 – 77.13
Table 6  Average personnel-
related reprocessing costs 
($US). All manual reprocessing 
is carried out by trained 
cleaning personnel at Odense 
University Hospital. Times 
spent on reprocessing were 
obtained by observing several 
reprocessing procedures
Job description related to reprocessing Average minutes spent on reprocessing 
after each procedure
Average cost of 
reprocessing
Transportation of bronchoscopes 0.5 0.29
Manual precleaning 6 3.53
Cleaning of worktable and table cart 1 0.59
Placement in drying cabinets 1.5 0.88
Daily cleaning of automated endoscope repro-
cessor
6 3.53
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twice when using a cDLT; however, in this study, fiberoptic 
confirmation was needed an average of 3.14 ± 1.58 times 
per procedure. In comparison, fiberoptic confirmation was 
only used two times for all the VivaSight-DL procedures 
(6.66% of the procedures), resulting in a significantly lower 
average bronchoscope use of 0.07 ± 0.25 times per procedure 
(p < 0.001). Moreover, only one of the fiberoptic confirma-
tions was related to the use of VivaSight-DL, whereas the 
other was used to check for bleeding and tumor mass in the 
lower respiratory tract. The average cost of VivaSight-DL 
including the need for a bronchoscope in 6.66% of the proce-
dures was $US299.96. Thus, the base-case results indicated 
that VivaSight-DL was less costly and more effective than 
cDLT in regard to fiberoptic confirmation. Table 7 presents 
the base-case results along with an overview of the one-
way sensitivity analyses. Figure 2 shows that the equivalence 
point is 15.8%, which is the percentage of VivaSight-DL 
cases involving verifying correct tube placement using a sin-
gle-use bronchoscope (aScope™ 4 Broncho) at which point 
VivaSight-DL is no longer associated with cost savings. 
Figure 3 shows the results of the two-way analyses, illus-
trating which of the two interventions is more advantageous 
when adjusting for the cost of VivaSight-DL and the cost 
of cDLTs with reusable bronchoscopes. Additionally, the 
PSA indicates that VivaSight-DL is more effective for avoid-
ing fiberoptic confirmation with a bronchoscope and less 
costly than cDLTs, as 100% of all the calculated ICERs are 
located in the south-eastern quadrant. A scatterplot of the 
PSA results is shown in Fig. 4, with an ellipse indicating the 
95% confidence interval.
4  Discussion
This study is the first to report the results of an economic 
evaluation comparing the use of VivaSight-DL and a cDLT 
in OLV procedures. The cost of using VivaSight-DL was 
$US299.96 per procedure, and the cost of using a cDLT 
with bronchoscopy was $US347.61, leading to an annual 
saving of approximately $US28,600 (13.7%) if all cDLTs 
were substituted with VivaSight-DL at OUH. Reprocessing, 
maintenance, and repairs of reusable bronchoscopes contrib-
uted to approximately 80% of the total cost in the control 
Table 7  Base-case result and one-way sensitivity analyses
Costs are presented in $US
cDLT conventional double-lumen tube, DL double-lumen tube
Scenario ∆ cost ∆ effect (avoided 
bronchoscopy)
ICER (cost per 
avoided bronchos-
copy)
Base case − 47.66 0.9333 − 51.06
One-way sensitivity analyses
 Using single-use bronchoscope (aScope™) in 5% of all VivaSight-DL cases (n = 30) − 32.71 0.9500 − 34.43
 Using single-use bronchoscope (aScope™) in 10% of all VivaSight-DL cases (n = 60) − 17.76 0.9000 − 19.73
 Using single-use bronchoscope (aScope™) in 15% of all VivaSight-DL cases (n = 90) − 2.81 0.8500 − 3.30
 Increasing annual number of procedures, n = 800 − 41.22 0.9333 − 44.17
 Increasing annual number of procedures, n = 1000 − 103.30 0.9333 − 110.68
 Increasing annual number of procedures, n = 1200 − 168.02 0.9333 − 180.03
 Decreasing maintenance costs by additional 10% (n = 600) − 39.05 0.9333 − 41.84
 Decreasing maintenance costs by additional 15% (n = 600) − 34.75 0.9333 − 37.23
 Decreasing maintenance costs by additional 20% (n = 600) − 30.45 0.9333 − 32.62
 Decreasing cost of VivaSight-DL by 10% (n = 600) − 77.65 0.9333 − 83.20
 Decreasing cost of VivaSight-DL by 20% (n = 600) − 107.65 0.9333 − 115.34
 Decreasing cost of VivaSight-DL by 30% (n = 600) − 137.64 0.9333 − 147.48
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Fig. 2  Equivalence point for when VivaSight-DL used with a single-
use bronchoscope (aScope™4 Broncho) no longer is associated with 
cost savings. Annual number of procedures: 600. cDLT conventional 
double-lumen tube, DL double-lumen tube
166 S. Larsen et al.
group. Furthermore, bronchoscopy was only necessary in 
two (6.66%) cases involving VivaSight-DL, and only one 
of these cases was necessitated by issues with the device 
(i.e., the novice physician was unable to sufficiently clean 
the camera lens due to secretions and blood). The ICER in 
this study was − $US51.06 per bronchoscopy avoided. As 
the ICER was negative, it can be difficult to interpret, as the 
intervention (VivaSight-DL) is already showing a greater 
effect and lower costs than using cDLT with bronchoscopy. 
Therefore, VivaSight-DL will always lead to a saving in 
regards to cost per avoided bronchoscopy, which raises ques-
tions over whether it makes sense to interpret a negative 
ICER in a case like this. Sensitivity analyses supported the 
findings of this study. However, the use of VivaSight-DL 
with a bronchoscope is only associated with cost savings 
when using a single-use bronchoscope (aScope™ 4 Bron-
cho). Figure 2 illustrates that an aScope™ 4 Broncho can 
be used with VivaSight-DL in up to 95 VivaSight-DL pro-
cedures annually (15.8%) and still be more cost saving than 
cDLTs with reusable bronchoscopes. VivaSight-DL is most 
likely not associated with cost savings if used with a reusa-
ble bronchoscope because of the high costs related to capital 
costs, reprocessing, maintenance, and repair of the reusable 
bronchoscopes. Thus, VivaSight-DL will only function as a 
more expensive tube and the advantages of the embedded 
camera will be inessential.
The main limitations of this study are the fact that the 
novice intubating physicians were not blinded to the device 
they were using, thus increasing the risk of potential biases. 
Another limitation is that all clinical data were measured and 
obtained by the novice physicians and other personnel them-
selves, which may increase the risk of biases compared with 
data collected by a study nurse or an unbiased investigator. 
However, the chosen effectiveness measure was not sensi-
tive to measurements as it was simple to identify whether a 
bronchoscope was used or not during the procedure. Further-
more, the chosen effectiveness measure in this study is not 
a health-related measure, which constitutes another weak-
ness, as health-related effectiveness measures are preferred 
in health economics [33]. However, health-related effects 
can be difficult to obtain when working with medical devices 
such as DLTs. The effect of the device cannot be measured 
directly on the patient, and the patients cannot assess the 
effect themselves as they are under full anesthesia. Costs 
related to training and education of cleaning personnel were 
not included as these data were not available, which consti-
tutes another limitation. Lastly, dropouts meant it was neces-
sary to enroll an additional 20 patients to reach a minimum 
Fig. 3  Two-way sensitiv-
ity analyses. The blue area 
indicates savings from using 
VivaSight-DL and the red area 
indicates savings from using 
reusable bronchoscopes. DL 
double-lumen tube
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of 50 eligible patients in the RCT. As an unequal number of 
patients were excluded from each group, an imbalance was 
created (30 vs. 22 patients), which was another limitation.
Uncertainties regarding costs were accounted for in the 
different sensitivity analyses; VivaSight-DL was associated 
with cost savings in every scenario compared with a cDLT. 
Multiple studies have already documented the numerous 
superior effects of VivaSight-DL compared with cDLTs in 
clinical settings, which further underlines the advantage of 
using VivaSight-DL as a tool for intubation in OLV proce-
dures [1, 4, 5, 12, 15]. Levy-Faber et al. [5] and Schuep-
bach et al. [12] found that bronchoscopy was unnecessary 
when intubating patients with VivaSight-DL, which supports 
the findings of this study indicating that bronchoscopy use 
can be minimized when using VivaSight-DL. When used 
by experienced physicians, VivaSight-DL may result in 
even fewer bronchoscopies, but this was not assessed in 
this study. Levy-Faber et al. [5] found that VivaSight-DL 
enables significantly quicker intubation compared with a 
cDLT, which is further supported by the findings of an RCT 
published by Heir et al. [15] in 2018. However, the current 
study showed that the intubation time was prolonged when 
using VivaSight-DL compared with a cDLT (p = 0.35). The 
prolonged intubation time was mainly because of one out-
lier and may be because the novice physicians had more 
experience with placing cDLTs than with VivaSight-DL. 
In addition, one physician mentioned that the continuous 
visualization meant the tube placement was more thorough 
in the VivaSight-DL group. Another study by Heir et al. [2] 
published in 2014 demonstrated that video-enabled DLT 
required fiberoptic confirmation of tube placement (for 
both initial placement and final verification after the patient 
was placed in the lateral surgical position) in significantly 
fewer cases (6.8%). Heir et al. [2] emphasized that this is in 
contrast to current standard practice, which always requires 
bronchoscopy for confirmation of correct tube placement, 
and that the addition of an integrated camera may increase 
patient safety [34].
The clinical advantages of VivaSight-DL are well-
documented, and the complete elimination of any risk of 
device-related cross-contamination because of its single-
use modality is a major benefit [2, 5, 35, 36]. However, if 
VivaSight-DL is used together with a reusable bronchoscope, 
the risk of cross-contamination will once again be present 
[2, 5]. Currently, none of the clinical advantages have been 
assessed in terms of the cost effectiveness of VivaSight-DL 
compared with cDLTs. Contaminated bronchoscopes have 
been linked to many nosocomial infections, although the 
true incidence of these infections is unknown because of 
inadequate surveillance [35–37]. Reusable bronchoscopes 
can be reprocessed, but they cannot be sterilized, which 
increases the risk of colonization by biofilm-producing spe-
cies [35, 38, 39]. Additionally, although maintenance costs 
were estimated from the literature and adjusted by -20%, 
the cost of purifying the water used by the AER was not 
included and neither were the other general overhead costs. 
Numerous minor costs contribute to the overall cost per 
procedure involving a cDLT, such as exact water consump-
tion, electricity, and regular training and education of new 
cleaning personnel. Furthermore, time spent remaining up to 
date and compliant with guidelines regarding reprocessing 
and handling of flexible bronchoscopes along with report-
ing failures of reprocessing equipment all contribute to the 
overhead costs. These overhead costs are difficult to estimate 
and include in economic evaluations, and economic evalua-
tions often lack precision in terms of including all overhead 
costs [3, 16, 22, 40]. If all cost drivers were identified and 
included in the analysis, the cost per procedure involving a 
cDLT would inevitably increase and thereby make cDLTs 
with bronchoscopy an expensive choice [8, 22, 39]. Addi-
tionally, training costs associated with implementing a new 
intervention (i.e., VivaSight-DL) were not included, as the 
same method is used for intubation; the only difference is 
the embedded camera in the VivaSight-DL. Future studies 
should include aspects of both the clinical advantages of 
VivaSight-DL related to the use of bronchoscopy to verify 
correct tube placement, intubation time, and number of 
attempts, ease of insertion, and risk of cross-contamination 
and the economic aspects, to ensure a reasonable balance 
between both aspects.
5  Conclusion
The results of this study suggest that VivaSight-DL is asso-
ciated with cost savings compared with a cDLT for OLV 
procedures. However, when used with a bronchoscope, 
VivaSight-DL is only associated with cost savings when 
used with a single-use bronchoscope. To clarify whether 
VivaSight-DL is cost saving in larger or global clinical set-
tings, further economic evaluations should be performed.
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